Here are five new drug shortages and discontinuations, according to drug supply databases from the FDA and the American Society of Health-System Pharmacists.
- Bumetanide injection: Several manufacturers, including Fresenius Kabi, Hikma Pharmaceuticals, Novadoz Pharmaceuticals and Sagent Pharmaceuticals have reported a shortage of bumetanide injection, a cardiovascular drug used as a loop diuretic. The affected strength is 0.25 milligram/1 milliliter.
- Dopamine hydrochloride injection: Hospira has discontinued its dopamine hydrochloride in dextrose 5% injection, a cardiovascular medication used to treat shock and heart failure. The discontinued presentation is 800 milligram/500 milliliter.
- Dobutamine hydrochloride injection: Pfizer has discontinued its 12.5 milligram/1 milliliter strength of dobutamine hydrochloride injection, a cardiovascular drug often used in acute heart failure and shock.
- Methylprednisolone acetate injection: Multiple presentations of methylprednisolone acetate injection, a corticosteroid used to treat inflammation, are currently in shortage. Affected products include Pfizer’s Depo Medrol in 40- and 80-milligram/milliliter strengths, Eugia’s 40-milligram/milliliter vials and Sandoz’s 40- and 80-milligram/milliliter vials. The shortage is due to manufacturing delays and increased demand. Resupply dates range from September to November 2025.
- Sodium ferric gluconate complex injection: Sodium ferric gluconate complex in sucrose injection, used to treat iron deficiency anemia, is in shortage. Affected manufacturers include Sanofi-Aventis and Hikma. Both companies have placed the 62.5-milligram/5 milliliter vials on allocation, and no reason for shortage was provided.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.